Crying All the Way to the Bank
Pharmaceutical Executive
Despite generics' increasing market share and the slowed pace of blockbuster discoveries, the industry has reason for optimism. A recent IMS World Review report shows that audited global pharmaceutical sales grew 12 percent in 2001.
Despite generics' increasing market share and the slowed pace of blockbuster discoveries, the industry has reason for optimism. A recent IMS World Review report shows that audited global pharmaceutical sales grew 12 percent in 2001. The report tracks sales of approximately 90 percent of all prescription medications and certain over-the-counter products in 70 countries.
2001 Global Pharmaceutical Sales by Region
IMS estimates 2001 global pharma sales were $392 billion, with North America, Europe, and Japan accounting for 87 percent of that. North America was again the most dynamic region, garnering $181.1 billion-almost half
of total sales. Europe's growth was up 10 percent to $88 billion. Japan's grew slowly but steadily at 4 percent, reaching $47.6 billion. Latin Ameri-can sales were flat, while sales in Asia (excluding Japan), Africa, and Australia, increased 9 percent.
Leading Therapy Classes in 2001 Global Pharmaceutical Sales
The report showed that anti-ulcerants' 14 percent growth helped it remain the leading therapeutic class worldwide, as it has for the past 11 years, representing 6 percent of all sales. AstraZeneca's Prilosec (omeprazole)-with $6.1 billion in sales-represents 32 percent of the class. Cholesterol reducers, ranked second, grew 22 percent to $18.9 billion. A major factor in that growth is the world's top-selling medicine, Pfizer's Lipitor (atorvastatin), which was up 31 percent to $7 billion.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
